<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05033743</url>
  </required_header>
  <id_info>
    <org_study_id>10283</org_study_id>
    <nct_id>NCT05033743</nct_id>
  </id_info>
  <brief_title>Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study</brief_title>
  <official_title>Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lupin Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effectiveness Secnidazole to treat recurrent BV.&#xD;
      Secnidazole is approved for one-time use in acute BV. In this study, the drug will be used&#xD;
      for recurrent BV, and given weekly for 18 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-center prospective pilot study with once-weekly oral secnidazole granule treatment&#xD;
      of acute condition for two-weeks followed by prophylactic treatment of asymptomatic&#xD;
      responders with once-weekly secnidazole for 16 weeks, followed by no therapy for 12 weeks.&#xD;
      The final follow-up evaluation is at week 28.&#xD;
&#xD;
      Eligible women with a current symptomatic bacterial vaginosis infection (&gt; or = 3 Amsel&#xD;
      criteria) and a history of at least 2 previous episodes of bacterial vaginosis in the past&#xD;
      year will be enrolled in the open-label treatment study. All women will be treated with 2g of&#xD;
      secnidazole granules orally once-weekly for 2 weeks. At the second visit, 3-5 days after&#xD;
      completion of treatment, women who have a resolution of bacterial vaginosis (asymptomatic and&#xD;
      &lt; or = 2 Amsel criteria) will continue on once-weekly secnidazole for 16 weeks.&#xD;
&#xD;
      Patients will be evaluated every 4 weeks for recurrence of bacterial vaginosis. This will&#xD;
      include questions about symptoms as well as a pelvic examination for assessment of vaginal&#xD;
      discharge (&gt; or = 3 Amsel criteria). We will also collect any information on other clinical&#xD;
      evaluations for recurrence and the dates of diagnoses and types of treatments they may have&#xD;
      received. Those who remain without recurrence during the 16-week suppressive phase will be&#xD;
      followed for an additional 12 weeks off therapy, with assessment for recurrence at weeks 22&#xD;
      and 30. Throughout the study, data will be collected on participants' compliance and on the&#xD;
      occurrence of adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Endpoint - Failed Treatment</measure>
    <time_frame>30 weeks</time_frame>
    <description>Number of subjects with at least one episode of bacterial vaginosis in the 30 week follow-up period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy Endpoint</measure>
    <time_frame>Days up to 210 days (30 weeks)</time_frame>
    <description>Time to failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy Endpoint</measure>
    <time_frame>30 weeks</time_frame>
    <description>Number of failures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>3-5 days after initial treatment</time_frame>
    <description>Amsel criteria or Nugent criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>week 6</time_frame>
    <description>Amsel criteria or Nugent criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>week 10</time_frame>
    <description>Amsel criteria or Nugent criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>week 14</time_frame>
    <description>Amsel criteria or Nugent criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>week 18</time_frame>
    <description>Amsel criteria or Nugent criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>week 22</time_frame>
    <description>Amsel criteria or Nugent criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>week 30</time_frame>
    <description>Amsel criteria or Nugent criteria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Participant compliance</measure>
    <time_frame>18 weeks</time_frame>
    <description>Subject compliance with the study medication, based on questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Participant tolerance</measure>
    <time_frame>18 weeks</time_frame>
    <description>Subject tolerance with the study medication, based on questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Participant adverse events</measure>
    <time_frame>30 weeks</time_frame>
    <description>Subject adverse events</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Recurrent Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secnidazole treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secnidazole 2 GM Oral Granules</intervention_name>
    <description>Once weekly 2g oral secnidazole for 18 weeks</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to consent in English&#xD;
&#xD;
          -  Current symptomatic bacterial vaginosis infection&#xD;
&#xD;
          -  History of at least 2 previous episodes of bacterial vaginosis in the past year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current gynecologic infection or condition, including candida vaginitis, gonorrhea,&#xD;
             chlamydia, trichomonas, desquamative inflammatory vaginitis, atrophic vaginitis.&#xD;
&#xD;
          -  Pre-existing heart conditions&#xD;
&#xD;
          -  Pre-existing neurological conditions&#xD;
&#xD;
          -  Currently Pregnant or breastfeeding&#xD;
&#xD;
          -  Women taking anticoagulants, lithium, metoclopramide, or disulfiram therapy&#xD;
&#xD;
          -  Hypersensitivity to secnidazole or other drugs in the same class.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chemen Neal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Graham A Hogg</last_name>
    <phone>3179620415</phone>
    <email>gahogg@iu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Indiana University Hospital - Coleman Center for Women</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graham A Hogg</last_name>
      <phone>317-962-0415</phone>
      <email>gahogg@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Chemen Neal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Haas, MD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peipert Jeffrey, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Chemen M. Neal</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Secnidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

